Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy…
By M. A. Nauck, M. Heimesaat, K. Behle, Jens J. Holst, M. Nauck, R. Ritzel, M. Hüfner, W. Schmiegel. Journal of Clinical Endocrinology and Metabolism, 2002
603 citations recorded by the source corpus.
Subfields: Endocrine and Autonomic Systems, Endocrinology, Diabetes and Metabolism
View Paper: https://www.semanticscholar.org/paper/9895ebaca0875ac7ae69370055f16e5ad5669197
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrine and Autonomic Systems
In Endocrinology, Diabetes and Metabolism
Citations in the corpus
- Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. (2005, methodology): “A: Control (n 9); B: VP (n 10); C: GLP-1 (n 13); D: exendin (9-39) and GLP-1 (n 6); E: Rp-cAMP and GLP-1 (n 6); F: LY294002 and GLP-1 (n 6); and G: UO126 and GLP-1 (n 6).”
- GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art (2020, background): “It also helped clarify the three main mechanisms leading to reductions in plasma glucose concentrations: (a) glucose-dependent insulinotropic actions [5], (b) suppression of glucagon hypersecretion [7] except during episodes characterized by hypoglycemia [10], and (c) a deceleration of gastric empty”
- Incretin hormones: Their role in health and disease (2018, background): “The absolute glycaemic threshold below which GLP-1 cannot stimulate insulin secretion, even at supra-physiological concentrations, was identified as approximately 66 mg dL.(24) Conversely, the higher the glucose concentrations, the greater the degree of augmentation.”
- The Role of Incretins in Glucose Homeostasis and Diabetes Treatment (2008, background): “Secretion of GLP-1 highly correlates with glucose level and insulin secretion, and its insulinotropic effects are observed at increased circulating glucose concentrations, but disappear once plasma glucose returns to normal (Nauck et al., 2002).”
- Enhancing incretin action for the treatment of type 2 diabetes. (2003, background): “Nevertheless, appropriate glucagon responses to hypoglycemia do not appear to be blunted in GLP-1– treated subjects (130), and GLP-1 infusion does not impair normal counterregulatory responses to hypoglycemia in healthy human subjects (131).”